Malvern company developing baldness treatment raising $20M

Aclaris Therapeutics Inc. entered into a $20 million stock purchase agreement Friday with a group of institutional accredited investors. The private placement, which involved the sale of nearly 1.1 million shares of common stock at a purchase price of $18.50 per share, is expected to close on or about June 2. Aclaris (NASDAQ: ACRS) plans to use the net proceeds from the offering to fund research and development activities, including its new JAK inhibitor programs for androgenetic alopecia — better…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news